Trametinib dimethyl sulfoxide

{
  "id": "MLC-T-ONC-008823",
  "term": "Trametinib dimethyl sulfoxide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with dabrafenib to treat low-grade glioma (a type of brain tumor) in children aged 1 year and older and certain types of anaplastic thyroid cancer, non-small cell lung cancer, melanoma, and other solid tumors that have a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Trametinib dimethyl sulfoxide blocks proteins called MEK1 and MEK2, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called Mekinist.",
    "A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth."
  ],
  "synonyms": [
    "Mekinist"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/trametinib-dimethyl-sulfoxide/"
}